The Food and Drug Administration has granted emergency use authorization to 
sotrovimab for the treatment of mild to moderate COVID-19 in patients at 
increased risk for progression to severe illness.Sotrovimab is a monoclonal 
antibody that works directly against the spike protein of SARS-CoV-2 to block 
its attachment and entry into a human cell.